# A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib

Source: https://onco.cc/trials/nct03673501/  
OnCo record `nct03673501` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Ripretinib and Sunitinib in gastrointestinal stromal tumour, run by Deciphera Pharmaceuticals, LLC, active and no longer recruiting.

## Summary

A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib is a phase 3 interventional study registered as NCT03673501 by Deciphera Pharmaceuticals, LLC, with 453 participants enrolled, started 2019-02-08 and due to reach its primary completion in 2021-09-01. Interventions recorded: Ripretinib and Sunitinib. Results have been posted on the registry.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-22
- Also known as: INTRIGUE
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03673501
- Phase: 3
- Setting: A Phase 3, Interventional, Randomized, Multicenter, Open-Label Study of Ripretinib vs Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST) After Treatment With Imatinib
- Sponsor: Deciphera Pharmaceuticals, LLC
- Enrolled: 453
- Outcomes: Progression Free Survival (PFS) in the KIT Exon 11 Intent to Treat (ITT) Population: Ripretinib 8.3 months vs Sunitinib 7 months, HR 0.88; Progression Free Survival (PFS) in the All Patient (AP) Intent to Treat (ITT) Population: Ripretinib 8 months vs Sunitinib 8.3 months, HR 1.05; Overall Survival (OS) in the KIT Exon 11 Intent to Treat (ITT) Population: Ripretinib 34 months vs Sunitinib 31.5 months, HR 1.05; Objective Response Rate (ORR) in the KIT Exon 11 Intent to Treat (ITT) Population Population: Ripretinib 23.9% vs Sunitinib 14.6%

## Sources

- ClinicalTrials.gov NCT03673501: https://clinicaltrials.gov/study/NCT03673501

## Connected records

- cancers: [Gastrointestinal stromal tumour (GIST)](https://onco.cc/cancers/gist/), [Imatinib-resistant GIST](https://onco.cc/cancers/gist-imatinib-resistant/)
- technologies: [Anti-angiogenic therapy](https://onco.cc/technologies/antiangiogenic/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Ripretinib](https://onco.cc/drugs/ripretinib/), [Sunitinib](https://onco.cc/drugs/sunitinib/)
- companies: [Deciphera Pharmaceuticals (Ono)](https://onco.cc/companies/deciphera/)

---
JSON: https://onco.cc/api/v1/entities/nct03673501.json